BIO-key Reports FY25 Revenue Down 14%, Widened Net Loss; Post-Split EPS Hits ($107.70)
BKYI sits 27% above its 52-week low of $3.1 on light trading volume (0.1× avg).
Summary
BIO-key International reported a 14.3% year-over-year revenue decline to $5.94M for fiscal year 2025. The company's net loss widened significantly to $7.16M, with diluted EPS of ($10.77). After adjusting for the 1-for-10 reverse stock split in April 2026, the equivalent post-split EPS loss is a staggering ($107.70). These results, detailed in the 10-K filed today, highlight severe financial distress, especially when considered alongside the recent Nasdaq delisting and a going concern warning. The substantial losses relative to the current stock price of $3.945 indicate significant operational challenges and raise serious questions about the company's viability.
At the time of this announcement, BKYI was trading at $3.95 on OTC in the Technology sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $3.10 to $19.70. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.